Gen-Z Influence on Pharma M&A
PharmExec
MARCH 14, 2024
Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.
Thu.Mar 14, 2024
52 
Elranatamab Maintains or Improves Symptoms and Health Status of Patients With Multiple Myeloma
Pharmacy Times
MARCH 14, 2024
This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan
STAT
MARCH 14, 2024
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.
FDA Breakthrough Therapy Designation Granted to Novel Psychedelic Molecule CYB003 for Major Depressive Disorder
Pharmacy Times
MARCH 14, 2024
At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
STAT
MARCH 14, 2024
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug
FDA Approves Resmetirom as First-Ever Treatment For MASH
Drug Topics
MARCH 14, 2024
The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
New Mayo Clinic program to qualify, integrate digital health offerings into clinical care
Fierce Healthcare
MARCH 14, 2024
Mayo Clinic wants to help digital health more quickly—and more cost-effectively—bring its innovations into the hospital. | The Mayo Clinic Platform's Solutions Studio program will work with digital health companies "from idea to integration into clinical workflows." The system pitches it as a cost-effective way for innovators to bring their offerings to the point of care.
STAT+: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.
STAT
MARCH 14, 2024
LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients. U.K. regulators approved the therapy , known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine.
FDA Approves Maralixibat for Treatment of Pediatric Patients With PFIC
Pharmacy Times
MARCH 14, 2024
The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.
STAT+: Argenx readies another blockbuster opportunity with its antibody drug
STAT
MARCH 14, 2024
Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
New Tool Helps Providers Navigate Adalimumab Biosimilars
Pharmacy Times
MARCH 14, 2024
The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.
Payers, providers continue to tussle over Change Healthcare cyberattack response
Fierce Healthcare
MARCH 14, 2024
Providers are still feeling the pain brought on by the cyberattack on Change Healthcare, and they're continuing to push insurers and the feds to beef up their responses. | Providers are still feeling the pain brought on by the cyberattack on Change Healthcare, and they're continuing to push insurers and the feds to beef up their responses.
Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech
Pharmaceutical Technology
MARCH 14, 2024
The funds will be used to expand Zephyr AI's headcount and enhance datasets.
Salesforce rolls out 'copilot' to automate tasks as tech giants ramp up focus on healthcare AI
Fierce Healthcare
MARCH 14, 2024
Salesforce launched a new healthcare AI assistant within its customer relationship management system, marking the latest tech company trying to expand its reach in the healthcare market. | Salesforce launched a new healthcare AI assistant within its customer relationship management system, marking the latest tech company trying to expand its reach in the healthcare market.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal
STAT
MARCH 14, 2024
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial. The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.
FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Pharmacy Times
MARCH 14, 2024
Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.
Interventional Techniques Can Help Manage Pain in Patients With Cancer
Drug Topics
MARCH 14, 2024
With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.
Nurses report wage, staffing dissatisfaction but most say they'll stick around until retirement, report finds
Fierce Healthcare
MARCH 14, 2024
Despite challenges with compensation, staffing shortages, safety and more, most nurses want to remain in the field until retirement, a new report found. | The report, which also covered nurses' thoughts on healthcare AI, included Incredible Health’s proprietary data from the 1 million nurses using its platform and the findings of a survey that reached more than 3,300 nurses working in the hospital setting.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Expert: A Functional Medicine Approach to Reversing Type 2 Diabetes Without Medication
Pharmacy Times
MARCH 14, 2024
Raj Gupta, DC, discusses holistic approaches to managing type 2 diabetes without medication by addressing root causes like diet, toxins, and stress.
BeiGene finally snags FDA approval for PD-1 drug Tevimbra after long delay, Novartis breakup
Fierce Pharma
MARCH 14, 2024
Twenty months after the FDA’s original target decision date on cancer drug tislelizumab, BeiGene has finally received the U.S. go-ahead. | Twenty months after the FDA's original target decision date, BeiGene has finally received the U.S. go-ahead for its PD-1 inhibitor Tevimbra.
Ruxolitinib Cream Could Provide Relief in Children Impacted by Atopic Dermatitis
Pharmacy Times
MARCH 14, 2024
The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.
Bristol Myers nabs new FDA nod as Breyanzi brings CAR-T class to chronic lymphocytic leukemia
Fierce Pharma
MARCH 14, 2024
Just as BeiGene’s Brukinsa encroaches on C | Just as BeiGene’s Brukinsa encroaches on CAR-T territory, Bristol Myers Squibb has brought its CAR-T therapy Breyanzi into chronic lymphocytic leukemia, which is considered the BTK inhibitor class’s home turf.
Pharmacist Expertise Is Critical to Antimicrobial Stewardship
Pharmacy Times
MARCH 14, 2024
Antimicrobial stewardship is crucial for all health care professionals—not just those in a hospital setting
AstraZeneca buys rare disease firm Amolyt for $1.05bn
pharmaphorum
MARCH 14, 2024
AstraZeneca adds a late-stage rare disease therapy to its pipeline, buying Amolyt Pharma and hypoparathyroidism drug eneboparatide for $800 million upfront.
NICE not sold on Vertex, CRISPR's groundbreaking sickle cell gene therapy Casgevy without more data
Fierce Pharma
MARCH 14, 2024
Ever since Vertex and CRISPR therapeutics scored a groundbreaking U.K. | In its draft guidance, the U.K.'s cost effectiveness watchdog recognized the need for the sickle cell therapy but needs more data from Vertex on its effectiveness in an updated managed access proposal.
Cybin bags breakthrough tag for psychedelic depression drug
pharmaphorum
MARCH 14, 2024
Cybin files a $150m placement on the back of new clinical data with its psychedelic drug CYB003 for depression and an FDA breakthrough designation.
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
STAT
MARCH 14, 2024
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development.
Deep learning model ‘detects 90% of lymphatic cancer cases’
pharmaphorum
MARCH 14, 2024
Researchers have developed an artificial intelligence algorithm to assist in the diagnosis of lymph node cancer from medical images that has an accuracy of around 90%. The team carried out a retrospective study on the deep learning model, using PET-CT scans from more than 5,000 patients treated for lymphoma at Memorial Sloan Kettering Cancer Centre in the US and the Medical University of Vienna in Austria.
STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more
STAT
MARCH 14, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are especially enjoying the Pharmalot grounds now that spring is springing and various work crews are dotting the nearby environs. This is an especially busy day for us, in fact, since we are hosting a session later on biosimilars — mark your calendar for 1 p.m.
Charles River inks viral vector production pact for Navega's chronic pain gene therapy
Fierce Pharma
MARCH 14, 2024
After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an adeno-asso | After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an adeno-associated virus 9 (AAV9) candidate meant to serve as a non-opioid alternative for rare disease patients li
Is CAR-T safe for early-stage patients?
STAT
MARCH 14, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues.
German biotech Tubulis raises €128m for ADC trials
pharmaphorum
MARCH 14, 2024
Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, particularly for companies with technologies that can enhance the safety of these drugs.
EMA pins lack of long-term data as rationale for Novartis’ failed Vijoice bid
Pharmaceutical Technology
MARCH 14, 2024
The EMA raised concerns about the lack of long-term data for Novartis Vijoice in its initial bid, as the Swiss company prepares for a new regulatory submission.
Let's personalize your content